The mutation rates of BRAF, SMAD4, and TP53 were 12.4% (384 patients), 16.6% (514 patients), and 65.6% (2025 patients) in the colorectal carcinoma cohort, respectively (Figure 5A–E). Here, BRAF is linked to colorectal carcinoma.